These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17633786)

  • 21. A strike against preemption.
    Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Editorial: Some caveats for the FDA.
    Calif Med; 1973 Oct; 119(4):64-5. PubMed ID: 4749314
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA regulations and guidelines.
    Rothschild A
    J Parenter Sci Technol; 1990; 44(1):26-9. PubMed ID: 2313489
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical trials from the industry viewpoint.
    McKinley RE
    J Am Vet Med Assoc; 1972 Dec; 161(11):1391-4. PubMed ID: 4638519
    [No Abstract]   [Full Text] [Related]  

  • 25. Foreign establishment registration and listing. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Nov; 66(228):59138-61. PubMed ID: 11776289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug Regulation Reform Act of 1978.
    Greenberg RB
    Am J Hosp Pharm; 1978 Jun; 35(6):729-32. PubMed ID: 665689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orphan Drug Act on congressional agenda.
    von Oehsen WH
    Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When does compounding become manufacturing?
    Gushee J
    J Am Vet Med Assoc; 1994 Jul; 205(2):235-6. PubMed ID: 7928585
    [No Abstract]   [Full Text] [Related]  

  • 29. View from the Nation's Capital.
    Romansky MA
    J Clin Psychopharmacol; 1984 Jun; 4(3):161-2. PubMed ID: 6096408
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA's role in drug product recalls.
    Crawford SY
    Am J Hosp Pharm; 1991 Dec; 48(12):2595-6. PubMed ID: 1814194
    [No Abstract]   [Full Text] [Related]  

  • 31. Generic vs. brand name drugs--quality, not cost, is key issue.
    Stetler CJ
    Internist; 1979 May; 20(4):9-10, 12. PubMed ID: 10242133
    [No Abstract]   [Full Text] [Related]  

  • 32. Dietary supplements: background for dialogue between the industry and the medical profession.
    Friede AI
    Food Drug Law J; 1998; 53(3):413-20. PubMed ID: 10346719
    [No Abstract]   [Full Text] [Related]  

  • 33. Unapproved drugs for export.
    Beardsley T
    Nature; 1986 Oct 23-29; 323(6090):657. PubMed ID: 3773992
    [No Abstract]   [Full Text] [Related]  

  • 34. II. Views of the pharmaceutical industry on the regulations.
    Newmark H
    Bull Parenter Drug Assoc; 1975; 29(5):218-21. PubMed ID: 1182331
    [No Abstract]   [Full Text] [Related]  

  • 35. Drug research and social profit.
    Markoe F
    Med Mark Media; 1978 Sep; 13(9):10, 12, 14 passim. PubMed ID: 10238519
    [No Abstract]   [Full Text] [Related]  

  • 36. Parenteral manufacturing and legal regulations.
    Tamura LK
    Bull Parenter Drug Assoc; 1968; 22(6):261-6. PubMed ID: 5727161
    [No Abstract]   [Full Text] [Related]  

  • 37. Wanted: complete control of drugs and doctors.
    Am Fam Physician; 1978 May; 17(5):69. PubMed ID: 655068
    [No Abstract]   [Full Text] [Related]  

  • 38. Another round over generics.
    Kosterlitz J
    Natl J (Wash); 1985 Oct; 17(42):2373, 2376. PubMed ID: 10274030
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug safety: a contrarian's point of view.
    Cobert B
    Food Drug Law J; 2007; 62(3):501-12. PubMed ID: 17915392
    [No Abstract]   [Full Text] [Related]  

  • 40. Reaction of FDA to a fundamental change in the nature of regulations.
    Kennedy D
    J Parenter Drug Assoc; 1979; 33(1):17-20. PubMed ID: 253023
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.